Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.26 +0.15 (+0.83%)
Official Closing Price Updated: 7:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Perfumes Of Arabia ↗
Downtrends do eventually run out of pessimistic steam, but it can take a while. 
Via Talk Markets
News headline image
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today ↗
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
News headline image
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials ↗
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the... 
Via Benzinga
News headline image
Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests ↗
Takeda Pharmaceutical was testing a drug called TAK-994 in narcolepsy patients. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
News headline image
Takeda Discontinues Two Mid-Stage Narcolepsy Trials ↗
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin... 
Via Benzinga
News headline image
Takeda Provides Update on TAK-994 Clinical Program
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA... 
Via Benzinga
News headline image
September Ends ↗
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Takeda In-Licenses Hunter Syndrome Candidate ↗
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to... 
Via Benzinga
News headline image
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug ↗
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in... 
Via Benzinga
News headline image
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
9 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for... 
Via Benzinga
News headline image
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
News headline image
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion ↗
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for... 
Via Benzinga
News headline image
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Pressure Day ↗
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
News headline image
ADHD Drug Developer Cingulate Plans NASDAQ Debut ↗
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Novavax Stock Is Slipping Again Today ↗
A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock. 
Via The Motley Fool
News headline image
Why Novavax Stock Surged Today ↗
The biotech's coronavirus-related revenue could be about to soar. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.